Crinetics Pharmaceuticals (CRNX) Total Non-Current Liabilities (2017 - 2026)
Crinetics Pharmaceuticals' quarterly Total Non-Current Liabilities came in at $115.8 million in Q1 2026, up 9.65% year-on-year from $105.6 million in Q1 2025, and down 11.6% quarter-over-quarter from $130.9 million in Q4 2025.
Crinetics Pharmaceuticals has reported Total Non-Current Liabilities for 6 years, with the latest figure at $115.8 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 9.65% year-over-year to $115.8 million; the trailing twelve-month figure through Mar 2026 stood at $115.8 million (up 9.65% YoY), and the FY2025 full-year result was $130.9 million, up 20.17% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $115.8 million, down from $130.9 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $130.9 million in Q4 2025, with the low at $96.2 million in Q4 2023.
- Average Total Non-Current Liabilities over 4 years is $111.4 million, with a median of $109.0 million recorded in 2024.
- Year-over-year, Total Non-Current Liabilities grew 20.17% in 2025 and increased 9.65% in 2026.
- Tracing CRNX's Total Non-Current Liabilities over 4 years: stood at $96.2 million in 2023, then grew by 13.21% to $109.0 million in 2024, then grew by 20.17% to $130.9 million in 2025, then dropped by 11.6% to $115.8 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $115.8 million (Q1 2026), $130.9 million (Q4 2025), and $121.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Crinetics Pharmaceuticals | 3.59 Bn | 3.59 Bn | 10.53 Mn | 115.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 115.75 Mn |
| Dec 31, 2025 | 130.93 Mn |
| Sep 30, 2025 | 120.97 Mn |
| Jun 30, 2025 | 115.71 Mn |
| Mar 31, 2025 | 105.56 Mn |
| Dec 31, 2024 | 108.96 Mn |
| Sep 30, 2024 | 103.88 Mn |
| Jun 30, 2024 | 104.57 Mn |
| Dec 31, 2023 | 96.25 Mn |
| Sep 30, 2018 | 9.16 Mn |
| Jun 30, 2018 | 6.91 Mn |
| Dec 31, 2017 | 920,000.00 |